ScholarLens Back to search
2007•Current Enzyme InhibitionRequires access

Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

Seiji Ueda, Sho‐ichi Yamagishi, Yuriko Matsumoto, Seiya Okuda

Open publisher page 0 citations

Abstract

Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD. Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO

About this research paper

What this paper is about

Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD. Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD. Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO

Key concepts: Asymmetric dimethylarginine, Kidney disease, Internal medicine, Endothelial dysfunction, Nitric oxide, Medicine, Arginine, Pathological

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease — Research Paper | ScholarLens